Chemotherapy

Arjun Vasant Balar; Matthew D. Galsky; Arlene O. Siefker-Radtke; Scott T. Tagawa; Matthew I. Milowsky

doi:10.1007/978-1-4939-1501-9_8

Chemotherapy

Arjun Vasant Balar, Matthew D. Galsky, Arlene O. Siefker-Radtke, Scott T. Tagawa, Matthew I. Milowsky

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

Urothelial cancer is a chemotherapy-sensitive pan-urothelial disease that arises from both the upper and lower urinary tract. Due to its rarity, the principles for management of upper tract urothelial cancer are derived from evidence gathered in bladder cancer trials. To date, no definitive evidence has differentiated upper tract from lower tract cancer and both are managed similarly. Epidemiologic observations, tissue-based genetic studies, and recent subset analyses from randomized trials suggest potential differences between upper tract and bladder cancers which will need to be validated in prospective trials. This chapter will review the current role for perioperative chemotherapy in high-grade upper tract urothelial cancer as well as the use of chemotherapy in advanced disease.

Original language	English
Title of host publication	Upper Tract Urothelial Carcinoma
Publisher	Springer New York
Pages	179-189
Number of pages	11
ISBN (Electronic)	9781493915019
ISBN (Print)	9781493915002
DOIs	https://doi.org/10.1007/978-1-4939-1501-9_8
State	Published - 1 Jan 2015

Keywords

Muscle-invasive bladder cancer
Renal pelvis cancer
Transitional cell cancer
Upper tract urothelial or transitional cell cancer
Ureter cancer
Urothelial cancer

Access to Document

10.1007/978-1-4939-1501-9_8

Cite this

@inbook{28abf23336ea41b8920a9145c4f9dd1c,

title = "Chemotherapy",

abstract = "Urothelial cancer is a chemotherapy-sensitive pan-urothelial disease that arises from both the upper and lower urinary tract. Due to its rarity, the principles for management of upper tract urothelial cancer are derived from evidence gathered in bladder cancer trials. To date, no definitive evidence has differentiated upper tract from lower tract cancer and both are managed similarly. Epidemiologic observations, tissue-based genetic studies, and recent subset analyses from randomized trials suggest potential differences between upper tract and bladder cancers which will need to be validated in prospective trials. This chapter will review the current role for perioperative chemotherapy in high-grade upper tract urothelial cancer as well as the use of chemotherapy in advanced disease.",

keywords = "Muscle-invasive bladder cancer, Renal pelvis cancer, Transitional cell cancer, Upper tract urothelial or transitional cell cancer, Ureter cancer, Urothelial cancer",

author = "Balar, {Arjun Vasant} and Galsky, {Matthew D.} and Siefker-Radtke, {Arlene O.} and Tagawa, {Scott T.} and Milowsky, {Matthew I.}",

year = "2015",

month = jan,

day = "1",

doi = "10.1007/978-1-4939-1501-9_8",

language = "English",

isbn = "9781493915002",

pages = "179--189",

booktitle = "Upper Tract Urothelial Carcinoma",

publisher = "Springer New York",

address = "United States",

}

TY - CHAP

T1 - Chemotherapy

AU - Balar, Arjun Vasant

AU - Galsky, Matthew D.

AU - Siefker-Radtke, Arlene O.

AU - Tagawa, Scott T.

AU - Milowsky, Matthew I.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Urothelial cancer is a chemotherapy-sensitive pan-urothelial disease that arises from both the upper and lower urinary tract. Due to its rarity, the principles for management of upper tract urothelial cancer are derived from evidence gathered in bladder cancer trials. To date, no definitive evidence has differentiated upper tract from lower tract cancer and both are managed similarly. Epidemiologic observations, tissue-based genetic studies, and recent subset analyses from randomized trials suggest potential differences between upper tract and bladder cancers which will need to be validated in prospective trials. This chapter will review the current role for perioperative chemotherapy in high-grade upper tract urothelial cancer as well as the use of chemotherapy in advanced disease.

AB - Urothelial cancer is a chemotherapy-sensitive pan-urothelial disease that arises from both the upper and lower urinary tract. Due to its rarity, the principles for management of upper tract urothelial cancer are derived from evidence gathered in bladder cancer trials. To date, no definitive evidence has differentiated upper tract from lower tract cancer and both are managed similarly. Epidemiologic observations, tissue-based genetic studies, and recent subset analyses from randomized trials suggest potential differences between upper tract and bladder cancers which will need to be validated in prospective trials. This chapter will review the current role for perioperative chemotherapy in high-grade upper tract urothelial cancer as well as the use of chemotherapy in advanced disease.

KW - Muscle-invasive bladder cancer

KW - Renal pelvis cancer

KW - Transitional cell cancer

KW - Upper tract urothelial or transitional cell cancer

KW - Ureter cancer

KW - Urothelial cancer

UR - http://www.scopus.com/inward/record.url?scp=84944041063&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-1501-9_8

DO - 10.1007/978-1-4939-1501-9_8

M3 - Chapter

AN - SCOPUS:84944041063

SN - 9781493915002

SP - 179

EP - 189

BT - Upper Tract Urothelial Carcinoma

PB - Springer New York

ER -

Chemotherapy

Abstract

Keywords

Access to Document

Fingerprint

Cite this